CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for the Final Recommendation for this drug and indication originally posted on March 7, 2013. The original axitinib (Inlyta) pCODR review can be found on the Inlyta for metastatic renal cell carcinoma (mRCC) details page: https://www.cadth.ca/inlyta-metastatic-renal-cell-carcinoma-mrcc-details.
| Project Number | pCODR RFA 0001 |
|---|---|
| Brand Name | Inlyta (RFA) |
| Generic Name | Axitinib |
| Tumour Type | Genitourinary |
| Indication | Metastatic Renal Cell Carcinoma |
| Request for Advice Question | RFA Question from the Provincial Advisory Group Is there evidence to fund axitinib as an alternative to everolimus for the second-line treatment of metastatic clear cell renal carcinoma? |
| Review Status | Notification to Implement Issued |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | pCODR Provincial Advisory Group |
| Submission Date | April 18, 2017 |
| Submission Type | Request for Advice |
| Stakeholder Input Deadline ‡ | May 2, 2017 |
| pERC Meeting | June 16, 2017 |
| pERC RFA Recommendation Issued | June 29, 2017 |
| Notification to Implement Issued | June 30, 2017 |
‡ Only stakeholders (e.g., submitter/manufacturer(s) of the drug(s) in question, patient groups and registered clinician(s)) who contributed to the original submission in question are eligible to provide input on the Request for Advice Question. Deadlines for Input are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
